TORONTO, May 5, 2016 /PRNewswire/ -- Replikins Ltd. today reported initial promising results in animal trials of its Zika vaccine candidates.
Logo - http://photos.prnewswire.com/prnh/20160505/364344LOGO
Photo - http://photos.prnewswire.com/prnh/20160505/364345
The company performed Replikins analyses of all Zika specimens recorded on Pubmed. The analysis identified the highest gene Replikin Counts in Zika history back to 1946 (1).
The Canadian biotechnology company then synthesized its first two Zika vaccine candidates in seven days. Administration to mice produced a statistically significant immune response in 21 days at p 0.0004 in Zika Vaccine RBA, and p 0.05 in Zika Vaccine RBB (see Figure).
In view of the current rapid spread of Zika, time to produce a vaccine candidate and time to generate a response to the vaccine are both relevant. The company will continue to make ‘real-time’ progress reports which may be useful to others working on the prevention of Zika and other zoonotic pandemics.
Contact: Samuel Bogoch, Email, Telephone 646-320-5910
References:
1. PRNewswire. May 2, 2016. Increases in Ebola and Zika Gene Replikin Counts for 2012 and 2013 Gave 1-3 Year Warning Before their Respective Outbreaks in 2014 and 2015.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/first-response-to-zika-replikins-vaccine-candidates-reported-300264043.html
SOURCE Replikins Ltd.
